Press Release

Global Defibrillator Market to Rise at 5.3% CAGR, Increasing Cases of Out of Hospital Cardiac Arrests to Provide Impetus, says Fortune Business Insights

Defibrillator Market: 2019 Potential Growth, Size, Share, Regional Analysis, Industry Outlook, Competitive Landscape, Trends, And Global Forecast To 2026

The Global Defibrillator Market is likely to expand considerably in the coming years due to the increasing incidence of out of hospital cardiac arrests. According to a report published by Fortune Business Insights, titled “Defibrillator: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 9,836.8 Mn in 2018. Fortune Business Insights states that the market will be valued at US$ 14,806.4 Mn by 2026, thereby exhibiting a CAGR of 5.3% during the forecast period.

Key players leading the global market include

  • Asahi Kasei Corporation,
  • Philips Healthcare,
  • Defibtech, LLC.,
  • Cardiac Science,
  • Stryker,
  • CU Medical System Inc.,
  • Medtronic Boston Scientific Corporation,
  • Biotronik,
  • LivaNova Plc

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/defibrillators-market-100950

Some major points from Table of Content:

  1. Introduction

1.1.Research Scope

1.2.Market Segmentation

1.3.Research Methodology

1.4.Definitions and Assumptions

  1. Executive Summary
  2. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4.Key Insights

4.1. Prevalence of Sudden Cardiac Arrests in Key Countries

4.2. Recent Industry Developments such as Mergers & Acquisitions

4.3. The Regulatory Scenario in Key Countries

4.4. New Products Launches by Key Players

4.5. Reimbursement Scenario for Key Countries

4.6. Key Industry Trends

  1. Global Defibrillator Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Type

5.2.1.Implantable Cardioverter Defibrillator (ICD)

5.2.1.1 Transvenous ICD

5.2.1.1.1. Single Chamber ICD

5.2.1.1.2. Dual Chamber ICD

5.2.1.1.3. CRT-D (cardiac resynchronization therapy- defibrillator)

5.2.1.2. Subcutaneous ICD

5.2.2. External Defibrillator

5.2.2.1. Automated External Defibrillator (AED)

5.2.2.2. Manual and Semi-automatic External Defibrillator

5.2.2.3. Wearable External Defibrillator

5.3. Market Analysis, Insights and Forecast – By End User

5.3.1. Hospitals & Clinics

5.3.2. Schools and other Public Places

5.4. Market Analysis, Insights and Forecast – By Region

5.4.1. North America

5.4.2. Europe

5.4.3. Asia pacific

5.4.4. Rest of the World

Boston Scientific Proposes a Defibrillator with 70% More Pacing Options

Boston Scientific receives FDA approval for its newest range of defibrillators, designed to better patient care. The company received approvals for Dynagen Mini and Inogen Mini, along with Dynagen X4 and Inogen X4. The company claims that the X4 lines of defibrillators offer 70% more pacing options for gathering elevated threshold levels. The size of these devices are what differentiates them from its counterparts and it has created a rising uptake within end users. The company has submitted on its website that these devices are approximately 20% smaller than the existing devices, produced by its counterparts. The approvals for Boston Scientific’s latest devices is likely to enable the growth of the global market in the forthcoming years.

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close